NEUROTECH

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety... Focusing on the development and commercialisation of neurological solutions.

Also known as: Neurotech International, Neurotech International Limited, Neurotech International Ltd

Primary location: Nedlands Australia